KN046 (PD-L1×CTLA-4) demonstrated clinically meaningful activity and tolerability with chemotherapy in metastatic non-small-cell lung cancer (157) and favorable outcomes in triple-negative breast cancer, particularly in PD-L1-positive disease (158). Here, CD274 is linked to non-small cell lung carcinoma.